Saeed Awad M Alqahtani

Dr. Saeed Awad M Alqahtani

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SASaeed Awad M Alqahtani
Saeed Awad M Alqahtani
Mucosal immunity plays a crucial role in defending against coronaviruses, particularly at respiratory sites, serving as the first line of defense against viral invasion and replication. Coronaviruses have developed various immune evasion strategies at the mucosal immune system, hindering the recognition of infected cells and evading antibody responses. Understanding the immune mechanisms and responses is crucial for developing effective vaccines and therapeutics against coronaviruses. The role of mucosal immunity in COVID-19 is significant, influencing both local and systemic immune responses to the virus. Although most clinical studies focus on antibodies and cellular immunity in peripheral blood, mucosal immune responses in the respiratory tract play a key role in the early restriction of viral replication and the clearance of SARS-CoV-2. Identification of mucosal biomarkers associated with viral clearance will allow monitoring of infection-induced immunity. Mucosally delivered vaccines and those under clinical trials are being compared and contrasted to understand their effectiveness in inducing mucosal immunity against coronaviruses. A greater understanding of lung tissue-based immunity may lead to improved diagnostic and prognostic procedures and novel treatment strategies aimed at reducing the disease burden of community-acquired pneumonia, avoiding the systemic manifestations of infection and excess morbidity and mortality. This comprehensive review article outlines the current evidence about the role of mucosal immune responses in the clearance of SARS-CoV-2 infection, as well as potential mucosal mechanisms of protection against (re-)infection. It also proposes that there is a significant role for mucosal immunity and for secretory as well as circulating IgA antibodies in COVID-19, and that it is important to elucidate this in order to comprehend especially the asymptomatic and mild states of the infection, which appear to account for the majority of cases. Moreover, it is possible that mucosal immunity can be exploited for beneficial diagnostic, therapeutic, or prophylactic purposes. The findings from recent studies on mucosal immunity in COVID-19 can be used to develop effective vaccines and treatments that can effectively target both mucosal and systemic immune responses.

29 September 2018 in Archives of Physiology and Biochemistry
Verified
Journal Article
Closed access
Manal S. FawzyManal S. Fawzy
Manal S. Fawzy
BABaraah AbuAlsel
Baraah AbuAlsel
EAEssam Al Ageeli
Essam Al Ageeli
SASaeed Awad M Alqahtani
Saeed Awad M Alqahtani
Mohamed Abdel-DaimMohamed Abdel-Daim
Mohamed Abdel-Daim
ETEman Toraih
Eman Toraih
Background: Circulating non-coding RNAs (ncRNAs) have been implicated in health and disease. This study aimed to evaluate the serum expression profile of microRNA-499a (miR-499a) and its selected bioinformatically predicted partner long-ncRNA MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) in diabetes-related end-stage renal disease (ESRD) patients and to correlate the expressions with the patients' clinicolaboratory data. Subjects and methods: Real-time quantitative polymerase chain reaction was applied in diabetics with and without ESRD (n = 90 for each). Results: Serum MALAT1 expression levels were increased in the ESRD group relative to diabetics without ESRD with median (quartile) values of 10.5 (1.41–126.7) (p < .001). However, miR-499a levels were decreased in more than half of ESRD patients with a median of 0.96 (0.13–3.14). Both MALAT1 and miR-499a expression levels were inversely correlated in the ESRD patient-group. Conclusions: MALAT1 up-regulation and miR-499 down-regulation might be involved in diabetic nephropathy-related ESRD pathogenesis. Functional validation studies are warranted to confirm the MALAT1/miR-499a partnership.

27 November 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
EREmad Rajih
Emad Rajih
ABAbdulaziz Bakhsh
Abdulaziz Bakhsh
WBWalaa M. Borhan
Walaa M. Borhan
SASaeed Awad M Alqahtani
Saeed Awad M Alqahtani
Prostate cancer management has long been challenged by the limitations of traditional screening tools like PSA testing, which contribute to significant rates of overdiagnosis and overtreatment. While advanced imaging such as multiparametric MRI (mpMRI) has improved the diagnostic pathway, the integration of Artificial Intelligence (AI) is now catalyzing a paradigm shift across the entire continuum of care. This comprehensive review details the transformative role of AI in prostate cancer. In diagnostics, deep learning algorithms enhance the interpretation of mpMRI by improving lesion detection, segmentation, and risk stratification, thereby reducing unnecessary biopsies. In digital pathology, AI provides automated and consistent Gleason grading, minimizing inter-observer variability and refining prognostication. In the therapeutic domain, AI is crucial for personalizing treatment by streamlining radiotherapy planning through automated contouring, predicting patient outcomes and toxicity, and enabling the development of adaptive therapy strategies for advanced disease. Multimodal AI models that synthesize imaging, biomarker, and clinical data are creating robust predictive tools for superior clinical decision support. Despite formidable challenges related to prospective validation, data equity, and regulatory approval, AI is paving the way for a new standard of care characterized by greater precision, efficiency, and personalization.

8 May 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MMMoaz A. Mojaddidi
Moaz A. Mojaddidi
MAMoutasem Aboonq
Moutasem Aboonq
SASaeed Awad M Alqahtani
Saeed Awad M Alqahtani
This review explores the critical interplay between glycemic control, mucosal immunity, and vaccine response in diabetic patients. Diabetes mellitus, characterized by impaired glucose regulation, significantly impacts immune function, particularly at mucosal surfaces. Poor glycemic control diminishes vaccine-induced antibody responses and compromises mucosal defenses, such as secretory IgA production, increasing susceptibility to infections. We synthesize evidence highlighting the importance of optimizing glycemic management prior to vaccination to enhance immunogenicity. Furthermore, we examine the potential of personalized vaccination strategies, tailored to individual glycemic status, age, BMI, and kidney function, to improve vaccine efficacy in this vulnerable population. Additionally, we discuss the role of adjunct therapies, including probiotics, nutritional interventions, and lifestyle modifications, in modulating the gut microbiota and reinforcing mucosal barrier integrity. This review underscores the necessity for an interdisciplinary approach, integrating metabolic management with innovative vaccine designs, to maximize protection against infectious diseases in diabetic patients. Future research should prioritize longitudinal studies assessing both systemic and mucosal immunity and refine personalized vaccination strategies to ensure robust and durable protection.

1 December 2024 in Journal of King Saud University – Science
Verified
Journal Article
Open access
SASaeed Awad M Alqahtani
Saeed Awad M Alqahtani
HAHussah M Alobaid
Hussah M Alobaid
JAJamilah Alshammari
Jamilah Alshammari
SASafa A Alqarzae
Safa A Alqarzae
SASheka Aloyouni
Sheka Aloyouni
SASuliman Alomar
Suliman Alomar

7 May 2025 in Saudi Medical Journal
Verified
Journal Article
Open access
PDF file
SASaeed Awad M Alqahtani
Saeed Awad M Alqahtani
Objectives: To identify the factors associated with post-stroke depression (PSD) and develop a machine learning predictive model using a large dataset, considering sociodemographic, lifestyle, and clinical factors. Methods: Our 2025 study used data from the 2023 Behavioral Risk Factor Surveillance System, released in September 2024. Data processing was carried out using Google Colab and Python. We carried out descriptive statistics, logistic regression, and feature importance analyses (mutual information and adjusted mutual information). A total of 4 machine-learning models were trained and evaluated: random forest, decision tree, gradient boosting, and logistic regression. Model performance was assessed using the accuracy, precision, recall, harmonic mean of precision and recall (F1-score), and area under the curve - receiver operating characteristic (AUC-ROC). The best-performing model was fine-tuned using GridSearchCV with 5-fold cross-validation. Results: Increasing age, male gender, being married, higher income, and physical activity were associated with lower odds of PSD. Obesity, smoking, diabetes, and high cholesterol are associated with increased odds of PSD. Age and gender were the most informative features for predicting the PSD. Random forest demonstrated the best performance for predicting PSD (accuracy=0.73, precision=0.71, recall=0.77, F1-score=0.74, and AUC-ROC=0.81), which was further improved by hyperparameter optimization. Conclusion: Post-stroke depression’s complex etiology involves sociodemographic, lifestyle, and clinical factors, notably age and gender. A random forest model effectively predicts PSD, highlighting the need for comprehensive assessment, early intervention, and management of modifiable risks (obesity, smoking, and inactivity) to improve stroke survivors’ outcomes.